Summary of selected high-grade adverse effects observed in patients
| Adverse effect . | BTKi + VEN . | R-CHOP + VEN . | IC + VEN . |
|---|---|---|---|
| Grade 5 | 2∗/28 (7%) | 1†/13 (8%) | 2‡/21 (10%) |
| Grade ≥3 neutropenia | 13/28 (46%) | 8/11 (73%) | 17/19 (89%) |
| Grade ≥3 thrombocytopenia | 11/28 (39%) | 5/11 (45%) | 18/19 (95%) |
| Febrile neutropenia | 8/28 (29%) | 3/13 (23%) | 10/21 (48%) |
| Grade ≥3 infections§ | 10/28 (36%) | 4/13 (31%) | 9/21 (43%) |
| Adverse effect . | BTKi + VEN . | R-CHOP + VEN . | IC + VEN . |
|---|---|---|---|
| Grade 5 | 2∗/28 (7%) | 1†/13 (8%) | 2‡/21 (10%) |
| Grade ≥3 neutropenia | 13/28 (46%) | 8/11 (73%) | 17/19 (89%) |
| Grade ≥3 thrombocytopenia | 11/28 (39%) | 5/11 (45%) | 18/19 (95%) |
| Febrile neutropenia | 8/28 (29%) | 3/13 (23%) | 10/21 (48%) |
| Grade ≥3 infections§ | 10/28 (36%) | 4/13 (31%) | 9/21 (43%) |
IC, intensive chemotherapy; VEN, venetoclax.
Pneumonia due to unspecified organism, and Nocardia pneumonia
Subdural hematoma
Vancomycin-resistant Enterococci sp. bacteremia, and human herpes virus-6 viremia
Information was only available for some patients. Nocardia pneumonia, Pneumocystis jirovecii pneumonia, sepsis secondary to Serratia organism, vancomycin-resistant Enterococci sp. bacteremia, and human herpes virus-6 viremia, cholecystitis, pneumonia from an unspecified organism, pseudomonal pneumonia, pseudomonal urinary tract infection with bacteremia, Coccidioides, and Aspergillus brain abscess, Clostridium difficile colitis, cytomegalovirus infection, and cellulitis with an unspecified organism were the infections observed in the cohort; some patients had >1 grade 3/4 infectious adverse effect.